OS Therapies Reports First Quarter 2026 Financials and Provides Business Update
OS Therapies reported a Q1 2026 net operating loss of $10.4 million, driven by R&D and regulatory expenses, but confirmed a cash runway into 2027 following $11.2 million in recent financings and expected non-dilutive tax credits. Regulatory momentum is accelerating: the EMA has initiated rolling review of the conditional Marketing Authorization Application (MAA) for OST-HER2, and the company has aligned with the FDA, EMA, and ATGA on the design of the confirmatory Phase 3 trial required for approval.
Key figures
- Revenue
- 0
- Prv sale reference
- 195000000
- Weighted avg shares
- 38674000
- Warrant inducement bridge
- 5700000
- Registered direct offering
- 5500000
- Expected vat rnd credits july
- 2500000
- Expected vat rnd credits june
- 2000000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.